Cholesterol embolism or atheroembolism is a phenomenon where cholesterol crystals and atheroma debris such as cholesterol, platelets, and fibrins embolizes from proximal large arteries such as the aorta and its major branches to distal small arteries. Cholesterol embolism frequently occurs after the intraarterial procedures, but it can also occur spontaneously. Cholesterol embolism is an uncommon multisystemic disease where multiple organs are involved, including the brain, muscles, skin, eyes, kidneys, and gastrointestinal (GI) tract. Organ damage usually manifests when cholesterol crystals break off from atherosclerotic plaques and shower to downstream vascular beds causing mechanical obstruction and inflammatory response to the target organ. It is important to note that cholesterol embolism is separate from thromboembolism in which thrombus forms on top of atherosclerotic plaque and large emboli break off, causing sudden infarction. Cholesterol embolism is a more gradual process and causes end-organ damage overtime. Note that here the emboli are usually made of debris from atherosclerotic plaques; mainly, cholesterol crystals.
Another name for cholesterol embolism syndrome or atheroembolism is "blue or purple toe syndrome." Atheroembolism that causes digital vascular occlusion causes the syndrome. In this disease, embolisms usually occlude smaller diameter vessels, and hence peripheral pulses are often intact. Therefore, whenever distal gangrene, ulcers, and cyanosis are present, but the pulse is intact, then it is highly suggestive of blue or purple toe syndrome.
Predisposing risk factors for cholesterol embolism include male gender, hypertension, hyperlipidemia, diabetes mellitus, peripheral vascular disease, atherosclerosis of ascending aorta, renal failure, and advanced age. Other likely scenarios include the patients who undergo interventional vascular procedures, cardiovascular surgery, those with an aortic aneurysm, have increased inflammation, have received thrombolytic therapy, or are on anticoagulation. The most important predisposing factor to CES (cholesterol embolism syndrome) is atherosclerosis. The severity of atherosclerosis is directly associated with the chance of getting CES.
Cholesterol embolization syndrome occurs either spontaneously or after intraarterial procedures such as aortic or cardiac surgery or thrombolytic therapy. About 80% of cholesterol embolism results from the intraarterial procedure, while less than 5% atheroembolism is due to spontaneous cholesterol embolism.
The exact incidence of CES is not known, but the reported incidence of clinically evident cholesterol embolism in the literature is generally less than 3.5%. Cholesterol emboli are much more common in patients 60 years or older who have atherosclerotic heart disease. For instance, studies that have looked at the incidence of CES by doing an autopsy in elderly who died after some form of intraarterial procedure found evidence of atheroembolism 10% to 77% of the time. In contrast, few autopsy studies of the generalized patient population reported CES incidence of only 0.31 to 2.4 percent.
The presence of plaque in large-caliber arteries like aorta and its branches leads to spontaneous, traumatic, or iatrogenic plaque rupture. Plaque debris, including cholesterol crystals, fibrins, platelets, calcified debris embolize, and lodge into small to medium arteries causing mechanical occlusion. The combined effect of mechanical occlusion and resultant inflammation from the foreign body, leukocyte infiltration, and complement activation, leads to end-organ damage.
Cholesterol crystal embolization is seen on microscopic examination as an arterial lumen filled with large cholesterol crystal spaces or clefts surrounded by hyperplastic intimal tissue and giant cells. Cholesterol crystal spaces are seen as crystals dissolve during the preparation.
Typical history in the patients with cholesterol embolization will most commonly include recent endovascular procedures such as heart catheterization, valve replacement, stent placement in the vasculature, or carotid endarterectomy. Usually, the patients will have risk factors similar to risk factors for atherosclerosis. The patients are likely to have a medical history of coronary artery disease, hypertension, hypercholesterolemia, cerebrovascular accident, transient ischemic attack, diabetes, abdominal aortic aneurysm, peripheral vascular disease, or renal failure.
Patients with cholesterol embolization syndrome frequently present with constitutional symptoms such as fever, fatigue, weight loss, myalgia, and anorexia. Besides, there are organ-specific clinical manifestations. In CES, the three most commonly affected organ systems are kidney (31.5%), skin (15.5%), and gastrointestinal (GI) tract (13.4%).
In the kidneys, atheroembolism causes two types of manifestations: acute to subacute or chronic. Acute or subacute form of kidney injury from embolization manifests clinically as microscopic hematuria, eosinophiluria, and minimal proteinuria on urine analysis. Whereas, chronic form most often manifests as heavy, nephrotic range proteinuria. CES should be a differential diagnosis when the intrinsic renal disease is suspected and especially in the case where secondary focal segmental glomerulosclerosis is high on the differential.
The involvement of the GI tract leads to the development of symptoms that include abdominal pain, flank pain, back pain, GI bleed, bowel ischemia, infarction, or obstruction, splenic infarction, pancreatitis, cholecystitis, abnormal liver enzymes, and diarrhea.
The most characteristic finding in skin includes retiform purpura, blue or purple toes, ulcers, gangrene, livedo reticularis, small nail bed infarcts, and foot or toe pain. Clinically these signs are seen when cholesterol emboli cause non-vasculitic occlusion of cutaneous blood vessels, especially after endovascular procedures.
On lab work, usually, signs of systemic inflammation are seen. Complete blood count (CBC) can show evidence of anemia, leukocytosis, thrombocytopenia. Hypereosinophilia, hypocomplementemia, elevated amylase, lipase, lactate, elevated LDH, elevated ESR, and high CRP levels are also possible. Urine analysis (UA) can show hematuria, eosinophiluria, and proteinuria of varying degrees. The renal function panel shows evidence of chronic kidney disease or acute kidney injury.
There is no specific laboratory test for cholesterol embolization syndrome. However, as mentioned above, a basic lab workup with CBC with cell count differential, complete metabolic panel (CMP), and UA can help. The retinal exam should be done in case the presentation of amaurosis fugax or sudden blindness to look for "Hollenhorst plaques." The only way to confirm the diagnosis of CES is the biopsy of various organs such as skin, skeletal muscles, gut mucosa, bone marrow, or kidneys. For instance, one study in the literature showed that non-renal biopsies identify cholesterol crystals in about 80% of the cases.
Depending on which organ is affected by cholesterol embolization, the evaluation and management of CES can be different. For instance, if stroke-like symptoms are seen in a patient, then CT scan of brain and MRI of the brain without contrast as well as MRA of the head and neck, are indicated. For acute limb ischemia, a CT angiogram should be considered based on the urgency of the presentation. If bowel ischemia is suspected, then the laboratory workup should include serum lactate and white blood cell count. In addition, high-resolution CT angiography should be considered to evaluate for bowel ischemia. In the case of suspected renal emboli, UA with proteinuria, eosinophiluria, or elevated LDH on the bloodwork should be seen. The renal US or high-resolution CT angiography should be done to diagnose renal emboli. Sometimes if the source is suspected to be valvular, then transesophageal echocardiogram (TEE) is performed.
The diagnosis can also be made clinically when fulminant CES occurs within days after the endovascular procedure, usually accompanied by blue toes or livedo reticularis.
There is no specific treatment for cholesterol embolization syndrome. Acute treatment depends on which organ embolization has occurred to, duration of symptoms, and type of emboli. Usually, treatment in acute settings is mostly supportive. When there are no other indications, anticoagulation should be stopped in patients suspected of having CES as it can worsen the condition.
Long term treatment includes identifying the source of the emboli and preventing its further spread and risk modifications. Patients who have clots formed in heart structures are anticoagulated. Patients with atherosclerosis of the larger arteries are usually treated with antiplatelet agents and statins (HMG-CoA reductase inhibitors) to stabilize the plaques. Further cardiovascular procedures, if possible, should be avoided as they are a known precipitant. Since the end-stage renal disease is the most common life-threatening complication, an aggressive approach in treating hypertension and regularly monitoring renal function is beneficial in long term management.
The differential diagnosis of CES includes various conditions that produce both microvascular ischemia of various organs and systemic inflammation. These include the small- to medium-vessel vasculitis (Takayasu disease, polyarteritis nodosa, Henoch-Schonlein purpura), antiphospholipid syndrome, infective endocarditis, thrombotic thrombocytopenic purpura, disseminated intravascular coagulation, cryoglobulinemia, and left atrial myxoma. Cancer such as lymphoma and diseases such as polycythemia vera, pheochromocytoma, Raynaud phenomenon, and tuberculosis are other possible differentials. In specific cases where some contrast agents are used, and the patients develop renal failure because of CES, the most common differential diagnosis is radiocontrast nephropathy. Other potential differentials are rapidly progressive glomerulonephritis, focal segmental glomerulonephritis, and hypertensive nephrosclerosis.
Patients diagnosed with cholesterol embolization syndrome have a poor prognosis due to cardiovascular comorbidities. One and two-year study rates are 87% and 75% respectively and a 4-year survival rate drops as low as 52%. Mortality has been cited in the literature to be as high as 63% to 81%.
Complications of cholesterol embolization syndrome depend on where the source of emboli is and in which organ arterial embolism is occurring. As discussed earlier, possible complications of CES include hypertension, bowel ischemia, renal insufficiency, stroke, end-stage renal disease, pancreatitis, cholecystitis, splenic infarction, carotid stenosis, blindness, skin rashes, myocardial ischemia, multiorgan failure, and death.
The treatment of cholesterol embolization syndrome is primarily medical, consisting of risk factor reduction. Patients should be educated about ways to reduce their risk factors. Diet and exercise should be advised to help with blood pressure control. Smoking cessation should be strongly recommended. The importance of medication compliance and regular follow up at the appointments, especially primary care physician and nephrology follow-up, should be stressed. Surgical or endovascular treatment may be indicated if a clear embolic source is identified, and the patient is an appropriate candidate for surgery. In that case, time should be taken to clearly explain to the patient the risk versus benefits of the indicated treatment. The patient should be given an idea about the prognosis, and discussion should be initiated about the code status and advance directives.
An interprofessional team that provides a holistic and integrated approach to care can help achieve the best possible outcomes. The medical teams, including nephrology, cardiology, rheumatology, radiological team; and, general and vascular surgical team must join their experience to make a decision between the hazards of treatment and the risk of CES. A dietician should be consulted to give patients with CES appropriate parenteral nutrition if needed. Pharmacists should be asked to ensure that all medications are appropriately dosed for the patient. Nurses should be notified to watch for any new cutaneous manifestations that appear on the patient's body. The earlier signs and symptoms of a complication are identified, the better the prognosis and outcome. Because patients with CES who have delayed reperfusion end up having greater ischemic damage to the organ. One major complication of CES is an end-stage renal disease, so care should be taken to preserve a site for the possible AV fistula creation in case the patient needs dialysis. Primary care physicians should be contacted and updated about the goals of care, including aggressive risk factor modifications for high-quality continued care to the patient. Palliative care should be consulted, and the family should have a good discussion with the palliative care team to understand options of patient care going forward as many patients have a high mortality burden. [Level 3]
|||Quinones A,Saric M, The cholesterol emboli syndrome in atherosclerosis. Current atherosclerosis reports. 2013 Apr; [PubMed PMID: 23423524]|
|||Dumazer P,Soula P,Soula-Bisseuil I,Modesto A,Bonafé JL,Suc JM, [Systemic embolism of cholesterol crystals]. La Revue du praticien. 1994 May 1; [PubMed PMID: 7939345]|
|||Li X,Bayliss G,Zhuang S, Cholesterol Crystal Embolism and Chronic Kidney Disease. International journal of molecular sciences. 2017 May 24; [PubMed PMID: 28538699]|
|||Ozkok A, Cholesterol-embolization syndrome: current perspectives. Vascular health and risk management. 2019; [PubMed PMID: 31371977]|
|||Tartari F,Di Altobrando A,Merli Y,Patrizi A,Mirelli M,Bianchi T, Blue Toe Syndrome: A Challenging Diagnosis. Indian journal of dermatology. 2019 Nov-Dec; [PubMed PMID: 31896856]|
|||Ghanem F,Vodnala D,K Kalavakunta J,Durga S,Thormeier N,Subramaniyam P,Abela S,S Abela G, Cholesterol crystal embolization following plaque rupture: a systemic disease with unusual features. Journal of biomedical research. 2017 Jan 19; [PubMed PMID: 28808190]|
|||Tazi-Mézalek Z,Filali N,Harmouche H,Adnaoui M,Aouni M,Mohattane A,Maaouni A,Berbich A, [Cholesterol crystal embolism]. Annales de cardiologie et d'angeiologie. 2000 Feb; [PubMed PMID: 12555320]|
|||Agrawal A,Ziccardi MR,Witzke C,Palacios I,Rangaswami J, Cholesterol embolization syndrome: An under-recognized entity in cardiovascular interventions. Journal of interventional cardiology. 2018 Jun; [PubMed PMID: 29243285]|
|||Tian M,Matsukuma KE, Cholesterol crystal embolism to the gastrointestinal tract: a catastrophic case. Autopsy [PubMed PMID: 31086777]|
|||Munawar T,Ibe U,Jiwa N,Raissi S, Renal cholesterol crystal embolism in the setting of warfarin use. BMJ case reports. 2019 Aug 21; [PubMed PMID: 31439554]|
|||Lazareth H,Karras A, Cholesterol Crystal Embolization after Transcatheter Aortic-Valve Replacement. The New England journal of medicine. 2019 Aug 15; [PubMed PMID: 31412179]|
|||Toriu N,Sumida K,Mizuno H,Hasegawa E,Suwabe T,Kawada M,Ueno T,Hayami N,Sekine A,Hiramatsu R,Yamanouchi M,Hoshino J,Sawa N,Takaichi K,Ohashi K,Fujii T,Ubara Y, Long-term outcome of biopsy-proven cholesterol crystal embolism. Clinical and experimental nephrology. 2019 Oct; [PubMed PMID: 31161263]|
|||Ben-Horin S,Bardan E,Barshack I,Zaks N,Livneh A, Cholesterol crystal embolization to the digestive system: characterization of a common, yet overlooked presentation of atheroembolism. The American journal of gastroenterology. 2003 Jul; [PubMed PMID: 12873565]|
|||Stone JR,Wilkins LR, Acute mesenteric ischemia. Techniques in vascular and interventional radiology. 2015 Mar; [PubMed PMID: 25814200]|
|||Imai N,Zamami R,Kimura K, Cutaneous cholesterol embolization syndrome. Indian journal of dermatology, venereology and leprology. 2015 Jul-Aug; [PubMed PMID: 26087104]|
|||Hirschmann JV,Raugi GJ, Blue (or purple) toe syndrome. Journal of the American Academy of Dermatology. 2009 Jan; [PubMed PMID: 19103358]|
|||Llamas-Velasco M,Alegría V,Santos-Briz Á,Cerroni L,Kutzner H,Requena L, Occlusive Nonvasculitic Vasculopathy. The American Journal of dermatopathology. 2017 Sep; [PubMed PMID: 27759698]|
|||Ogbechie OA,Morley KW,Sugai D,Nambudiri VE,Senna MM,Hoang MP,Saavedra AP, Limited cutaneous pseudovasculitis: a mild variant of cholesterol emboli syndrome. Circulation. 2015 Feb 3; [PubMed PMID: 25645613]|
|||Blackshear JL,Oldenburg WA,Cohen MD, Making the diagnosis when the patient has 'blue toes'. Geriatrics. 1994 Dec; [PubMed PMID: 7982584]|
|||Nijhof IS,Majoie IM,Dijkhorst-Oei LT,Bousema MT, [Blue toe syndrome; a sign of end-arterial occlusion]. Nederlands tijdschrift voor geneeskunde. 2007 Jun 9; [PubMed PMID: 17624153]|
|||Polakoff S, Decrease in acute hepatitis B incidence continued in 1987. Lancet (London, England). 1988 Mar 5; [PubMed PMID: 2893962]|
|||Rousseau A,de Monchy I,Barreau E,Yahiaoui Y,M'garrech M,Kaswin G,Labetoulle M, Retinal emboli in cholesterol crystal embolism. Case reports in ophthalmological medicine. 2013; [PubMed PMID: 24396621]|
|||Muehlenberg K,Faltermeier N,Pech O, The Cholesterol Embolism Syndrome. Deutsches Arzteblatt international. 2017 Apr 7; [PubMed PMID: 28446355]|
|||Maekawa M,Sugino N,Watanabe K,Nomura R, Multiple Brain Infarction Associated with Cholesterol Embolization Syndrome. Internal medicine (Tokyo, Japan). 2017 Sep 15; [PubMed PMID: 28824077]|
|||Saric M,Kronzon I, Cholesterol embolization syndrome. Current opinion in cardiology. 2011 Nov; [PubMed PMID: 21993354]|
|||Meyrier A, Cholesterol crystal embolism: diagnosis and treatment. Kidney international. 2006 Apr; [PubMed PMID: 16614719]|
|||Lyaker MR,Tulman DB,Dimitrova GT,Pin RH,Papadimos TJ, Arterial embolism. International journal of critical illness and injury science. 2013 Jan; [PubMed PMID: 23724391]|
|||Igarashi Y,Akimoto T,Kobayashi T,Iwazu Y,Miki T,Otani-Takei N,Imai T,Sugase T,Masuda T,Takeda SI,Muto S,Nagata D, Performing Anticoagulation: A Puzzling Case of Cholesterol Embolization Syndrome. Clinical medicine insights. Case reports. 2017; [PubMed PMID: 28469497]|
|||Varis J,Kuusniemi K,Järveläinen H, Cholesterol microembolization syndrome: a complication of anticoagulant therapy. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne. 2010 Jun 15; [PubMed PMID: 20308269]|
|||Vidt DG, Cholesterol emboli: a common cause of renal failure. Annual review of medicine. 1997; [PubMed PMID: 9046969]|